乳腺癌新辅助系统治疗后，溶剂型紫杉醇、脂质型紫杉醇、纳米颗粒结合白蛋白型紫杉醇和多西他赛的疗效比较。
Efficacy comparisons of solvent-based paclitaxel, liposomal paclitaxel, nanoparticle albumin-bound paclitaxel, and docetaxel after neoadjuvant systemic treatment in breast cancer.
发表日期：2023 Sep 15
作者：
Weiwei Zhang, Ye Wang, Jinzhi He, Yinggang Xu, Rui Chen, Xinyu Wan, Wenjie Shi, Xiaofeng Huang, Lu Xu, Jue Wang, Xiaoming Zha
来源：
Nanomedicine
摘要：
目前有四种紫杉醇制剂：基于溶剂的紫杉醇（Sb-P）、脂质体载药的紫杉醇（Lps-P）、纳米颗粒蛋白结合紫杉醇（Nab-P）和多西他赛。本研究旨在对乳腺癌新辅助全身治疗（NST）中不同紫杉醇的疗效进行回顾性评估。
纳入了2013年8月至2022年4月期间被诊断为乳腺癌并接受完整NST治疗的患者。对疗效进行了总体病理完全缓解（total-pCR）、乳腺病理完全缓解（breast-pCR）和腋窝病理完全缓解（axillary-pCR）的分析和讨论。
紫杉醇的选择是总体-pCR和乳腺-pCR率的独立风险因素。在纳入的紫杉醇制剂中，Nab-P组的总体-pCR和乳腺-pCR率最高。在腋窝-pCR率方面，各种紫杉醇之间的差异不显著。
Nab-P显著改善了总体-pCR和乳腺-pCR率。在乳腺癌NST治疗中，Nab-P应作为紫杉醇的首选。
版权所有 © 2023. Elsevier Inc. 发表
There are four kinds of taxanes: solvent-based paclitaxel (Sb-P), liposomal paclitaxel (Lps-P), nanoparticle albumin-bound paclitaxel (Nab-P), and docetaxel. This study aims to retrospectively evaluate the efficacy of different taxanes on neoadjuvant systemic treatment (NST) in breast cancer.Patients who were diagnosed with breast cancer and had received integral NST from August 2013 to April 2022 were enrolled. The efficacy was divided into total pathological complete response (total-pCR), breast pathological complete response (breast-pCR), and axillary pathological complete response (axillary-pCR) for in-depth analysis and discussion.The choice of taxane was an independent risk factor for total-pCR and breast-pCR rates. The highest total-pCR and breast-pCR rates were found in the Nab-P group. The difference was not significant among all the taxanes in the axillary-pCR rate.Nab-P significantly improved the total-pCR and breast-pCR rates. It should be the first choice among taxanes in NST for breast cancer.Copyright © 2023. Published by Elsevier Inc.